TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04289740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals
Description: Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.
Description: The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
Study: NCT05216900

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: The study examines the delivery NART.~In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied.~A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap.
Study: NCT06257992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: 3 treatments of dry needling to inactivate all active trigger points found in patient's cervical muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretch
Description: 3 treatments of stretch applied to all cervical muscles that present active trigger points in patient's cervical muscles.
Study: NCT06072560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adezunap (AP707)
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT05635916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
Study: NCT06396650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based training
Description: 1. If the participant shows instability in any specific perturbation directions or with excessive body swaying, the participant will practice walking with a cellphone strapped on the chest in-home training. A cellphone App will detect potential excessive body swaying in any directions and prompt the participant with real time audio-visual feedback to reduce sway in the specific directions.~2. If the subject is diagnosed with collapse-related vertical instability, lower-limb muscle strengthening will be emphasized in the training. The subject may work out with a Shuttle Mini-Press, AB Squat machine, Rowing machine, or Upright Row-n-Ride. The Investigators will select one machine appropriate for the subject to take home. The exercise will be 3-5 sets a day and about 15 repetitions per set. In the beginning, the exercise can be slower and with fewer repetitions based on the subject's capability. As the subject progresses, the subject may change from one exercise machine to another.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lab-based training
Description: In the weekly lab-based training session, the subject will do individualized training using the sliding stepping trainer, with a focus on the direction the subject showed higher risks of falling, as identified in the initial assessment. The sliding stepping trainer will generate perturbations of the footplates in those identified risky directions during stepping.
Study: NCT05729568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously
Study: NCT06654115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wireless Physiologic Monitoring
Description: YHE® BP Doctor Pro Blood Pressure Smartwatch, which is a commericially available device. The device can monitor heart rate, blood pressure and saturation.
Study: NCT06586710

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment activation of interferon pathway
Description: * Peripheral blood collection (as part of routine blood draws) on which interferon signature will be performed at the time of enrollment and in case of remission and/or any renal flare.~* Renal biopsies (routinely performed for diagnostic purposes and during clinical follow-up) on which Myxovirus resistance protein 1 (MXA) expression and histopathologic characterization will be assessed.~* Collection of clinical and laboratory data from routine visits performed at baseline and 3, 6, 12, and 24 months (or last available visit) after the renal biopsy was performed.
Study: NCT06603584

Intervention type: RADIATION
Intervention: Chest x- Rays
Description: prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe
Study: NCT05729568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Injection
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Injection
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Injection
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy
Description: Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
Study: NCT05208164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfunlness Meditation
Description: Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
Study: NCT06179498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner Navigation Intervention
Description: A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
Study: NCT04888520

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Adhesive elastic bandage
Description: The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive elastic bandage
Description: The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist.
Study: NCT05928091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call to an expert team
Description: Patients will be treated as the expert said when the investigator called him
Study: NCT04962789

Intervention type: DIAGNOSTIC_TEST
Intervention: transvaginal ultrasound on the uterus
Description: Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer

Intervention type: DIAGNOSTIC_TEST
Intervention: transvaginal ultrasound on the uterus
Description: Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer
Study: NCT05373524

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological analysis
Description: Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological analysis
Description: Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
Study: NCT05511623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
Study: NCT04923048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB261
Description: Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.
Study: NCT06603584

Intervention type: RADIATION
Intervention: Chest x- Rays
Description: prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe

Intervention type: RADIATION
Intervention: Chest x- Rays
Description: prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe

Intervention type: RADIATION
Intervention: Chest x- Rays
Description: prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe
Study: NCT06603922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological treatment (P-MCT)
Description: Personalization will be performed according to the results obtained from the platform. Both the classic MCT and personalized MCT will be the same with regard to specific modules that are offered to patients. However, the personalized MCT will have personalized homeworks that target specific factors, in which patients have deficits. For instance, patients with deficits in self-esteem (based on the results from the platform) will be provided with homework addressing this aspect. We identified five domains that will be personalized: 1. self-esteem; 2. cognitive insight; 3. delusions; 4. positive symptoms; 5. completion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological treatment (MCT)
Description: Metacognitive training is a cognitive approach to the treatment of positive symptoms in psychosis.~Metacognitive training consists of ten modules referring to common cognitive issues and biases in solving problems in schizophrenia. The topics of MCT include the following: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 \& 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5), mood (module 8), self-esteem (9) and stigma (10).~Each session lasts 45-60 min and follows a protocol defined in the 'Metacognitive Training for Psychosis (MCT)' manual.~The MCT for Schizophrenia programme will be applied to the group (6-12 persons) applied by therapists in each center. The training format (online or in-person) as well as the frequency (1 or 2 times per week) will vary depending on the center.
Study: NCT05317988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
Study: NCT05880017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.
Description: Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.
Description: Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine for peritoperative analgesia (control group).
Description: Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: As a local anesthetic will be injected in modified and conventional groups 20ml in each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
Study: NCT05938855

Intervention type: DEVICE
Group type: OTHER
Intervention: Electrical stimulation and biofeedback with the medical device Phenix Liberty
Description: The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.~The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 10 sessions between 10 and 12 weeks~* 1 end visit, within the week after the 10th session
Study: NCT05638750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Intervention
Description: 12-week treatment intervention \& home exercised, then 12-week non-intervention period, follow-up visit at end of non-intervention period.
Study: NCT06654336

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Recurrence-directed therapy (RDT)
Description: RDT options include radiotherapy or surgical resection.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Recurrence-directed therapy (RDT)
Description: RDT options include radiotherapy or surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIGARD 22.5mg
Description: ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
Study: NCT06592586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 vaccine
Description: 0.5 mL (50 μg GBS-NN +50 μg GBS-NN2 adsorbed to 0.5 mg aluminium as Alhydrogel®)
Study: NCT04975256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: SOS1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: SOS1 Inhibitor
Study: NCT06044922

Intervention type: DEVICE
Intervention: 24-hour Holter monitoring
Description: Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
Study: NCT06289673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenously (IV) for 1 dose on Day 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Description: Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT as part of Intrathecal triple therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT as part of Intrathecal triple therapy.
Study: NCT05832008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Nudge
Description: Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Nudge
Description: Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Nudge
Description: EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
Study: NCT06602622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Integrase inhibitor
Description: Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine + tenofovir DF + lamivudine
Description: Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
Study: NCT06593548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib (AK112)
Description: Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication. Depending on the dose limits of normal tissue radiation, Stereotactic Ablative Radiotherapy (SABR), large fraction radiotherapy, or high-dose combined with low-dose radiotherapy will be administered to primary and metastatic lesions. One week after completing radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment. If primary and metastatic lesions are too extensive for initial radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment until the lesions shrink, at which point radiotherapy may be considered.。
Study: NCT06604559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge using Apollo application
Description: Discharge using Apollo application

Intervention type: OTHER
Group type: OTHER
Intervention: Regular discharge
Description: Discharge with the regular process